Skip to main content
SpringerLink
Log in

Starting prostate cancer therapy with AA+P cost saving versus ENZ

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Brazilian Reals

Reference

  • Pititto L, et al. Cost Effectiveness of Abiraterone Acetate plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration-Resistant Prostate Cancer Patients Under the Brazilian Private Health Care System Perspective. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN85, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=45354

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Starting prostate cancer therapy with AA+P cost saving versus ENZ. PharmacoEcon Outcomes News 755, 36 (2016). https://doi.org/10.1007/s40274-016-3143-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3143-9

Search

Navigation